Type II Diabetes
Conditions
Sponsors
Novartis Farmaceutica S. A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male, non-fertile female (i.e., post menopausal, post hysterectomy, or sterilized by tubal ligation) or female of childbearing potential using a medically approved birth control method (e.g., hormonal contraceptives, IUD, double-barrier contraception). A female of childbearing potential using a medically approved birth control method must be willing to use the same method of contraception during the full course of the study. 2. Drug naïve patients with type 2 diabetes (drug naïve patients are defined as subjects who have had no treatment with oral antidiabetic agents for at least 12 weeks prior to study entry (visit 1) and no treatment with oral antidiabetic agents at any time in the past for > 3 consecutive months). 3. Age =18 years. 4. Body mass index (BMI) in the range of 20-40 kg/m2 inclusive at visit 1. 5. HbA1c in the range of 7.5%-11% inclusive at visit 1. 6. FPG ? 15 mmol/L (270 mg/dL) at visit 1. 7. Agreement to maintain prior diet and exercise habits during the full course of the study. 8. Written informed consent to participate in the study. 9. Ability to comply with all study requirements. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating female. 2. A history of: • type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing’s syndrome and acromegaly. • acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months. 3. Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis. 4. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1. 5. A history of: • Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation. • percutaneous coronary intervention within the past 3 months. • any of the following within the past 6 months: myocardial infarction (MI) (If the visit 1 ECG reveals patterns consistent with a MI and the date of the event cannot be determined, then the patient can enter the study at the discretion of the investigator and the sponsor); coronary artery bypass surgery; unstable angina; or stroke. 6. Congestive heart failure NYHA class III or IV. 7. Any of the following ECG abnormalities: • second degree AV block (Mobitz 1 and 2) • third degree AV block • prolonged QTc (> 500 ms) 8. Malignancy including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years. 9. Liver disease such as cirrhosis or chronic active hepatitis. 10. Acromegaly or treatment with growth hormone or similar drugs. 11. Chronic intestinal disorders associated with distinct disturbances of digestion and absorption, and conditions that may deteriorate as a result of increased gas formation in the intestine (e.g. Roemheld’s syndrome, major hernias, intestinal obstructions, and intestinal ulcers). 12. Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study. 13. Donation of one unit (500 mL) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks. 14. Contraindications and warnings according to the country specific label for acarbose not listed in the other exclusion criteria. 15. Known sensitivity to acarbose or related drugs. 16. Chronic insulin treatment (> 4 weeks of treatment in the absence of an intercurrent illness) within the past 6 months. 17. Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1. 18. Treatment with class Ia, Ib and Ic or III anti-arrhythmics. 19. Thyroid hormone replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within normal limits at visit 1. 20. Investigational drug treatment within 4 weeks prior to visit 1 unless local health authority guidelines mandate a longer period. 21. Treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months (i.e., cytostatic drugs). 22. Any of the following significant laboratory abnormalities: • ALT, AST greater than 3 times the upper limit of the normal range at visit 1. • Direct bilirubin greater than 1.3 times the upper limit of the normal range at visit 1. • Serum creatinine levels = 220 ?mol/L (2.5 mg/dL) at visit 1, or a history of creatinine clearance < 25 mL/min. • TSH outside of normal range at visit 1. • Clinically significant laboratory abnormalities, confirmed by repeat measurement, other than hyperglycemia, hyperinsulinemia, and glycosuria at vis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: 1.To demonstrate the efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that the hemoglobin A1c (HbA1c) reduction with LAF237 is not inferior to that with acarbose after 24 weeks of treatment;Secondary Objective: 1. demonstrate efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that, in the Chinese subset of the study population, the HbA1c reduction with LAF237 is not inferior to that with acarbose after 24 wks of treatment. 2. demonstrate the safety of LAF237 in patients with type 2 diabetes by showing that LAF237 has a similar overall adverse event profile (excluding gastrointestinal adverse events) compared to acarbose after 24 wks of treatment. 3.demonstrate the safety of LAF237 in patients with type 2 diabetes by showing that LAF237 has a superior gastrointestinal tolerability compared to acarbose after 24 wks of treatment. 4.demonstrate the efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that the fasting plasma glucose (FPG) reduction with LAF237 is not inferior to that with acarbose after 24 wks of treatment. ;Primary end point(s): HbA1c measured by ion exchange High Performance Liquid Chromatography (HPLC). | — |
Countries
Spain
Outcome results
None listed